Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells

Carcinogenesis

Volumn 28, Issue 6, 2007, Pages 1188-1196

  Non, Larisa ^a   Duong, David ^a   Peehl, Donna M ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(6) GINGEROL; CURCUMIN; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 5; PLANT MEDICINAL PRODUCT; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CANCER CELL CULTURE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; PROTEIN FUNCTION; UPREGULATION;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELLS, CULTURED; CURCUMIN; HUMANS; INFLAMMATION MEDIATORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; PHOSPHOPROTEIN PHOSPHATASE; PHYTOTHERAPY; PROSTATE;

EID: 34447330714     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl241     Document Type: Article

References (46)

1. Nelson,W.G. et al. (2004) The role of inflammation in the pathogenesis of prostate cancer. J. Urol., 172, S11-discussion S11-S12.
2. Coussens,L.M. et al. (2002) Inflammation and cancer. Nature, 420, 860-867.
3. Palapattu,G.S. et al. (2004) Prostate carcinogenesis and inflammation: Emerging insights. Carcinogenesis, 26, 1170-1181.
4. Platz,E.A. et al. (2005) Nonsteroidal anti-inflammatory drugs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol. Biomarkers Prev., 14, 390-396.
5. Fernandez,L. et al. (2005) Sexual behaviour, history of sexually transmitted diseases, and the risk of prostate cancer: A case-control study in Cuba. Int. J. Epidemiol., 34, 193-197.
6. Nonn,L. et al. (2006) Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: Implications for prostate cancer prevention by vitamin D. Cancer Res., 66, 4516-4524.
7. Krishnan,A.V. et al. (2005) Vitamin D and prostate cancer. In Glorieux,F.H. (ed.) Vitamin D. Elsevier Academic Press, San Diego, Vol. 2, pp. 1679-1707.
8. Peehl,D.M, et al. (2004) Molecular activity of 1,25-dihydroxyvitamin D(3) in primary cultures of human prostatic epithelial cells revealed by cDNA microarray analysis. J. Steroid Biochem. Mol. Biol., 92, 131-141.
9. Huang,X. et al. (2005) Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. Cancer Res., 65, 3470-3478.
10. Palmer,H.G. et al. (2003) Genetic signatures of differentiation induced by 1alpha,25-dihydroxyvitamin D3 in human colon cancer cells. Cancer Res., 63, 7799-7806.
11. Zhang,X. et al. (2005) Suppression of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3 revealed by microarray analysis. J. Biol. Chem., 280, 35458-35468.
12. Tanoue,T. et al. (1999) Molecular cloning and characterization of a novel dual specificity phosphatase, MKP-5. J. Biol. Chem., 274, 19949-19956.
13. Theodosiou,A. et al. (1999) MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene, 18, 6981-6988.
14. Zhang,Y. et al. (2004) Regulation of innate and adaptive immune responses by MAP kinase phosphatase 5. Nature, 430, 793-797.
15. Roux,P.P. et al. (2004) ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol. Mol. Biol. Rev., 68, 320-344.
16. Moreno,J. et al. (2005) Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res., 65, 7917-7925.
17. Harant,H. et al. (1997) 1alpha,25-dihydroxyvitamin D3 and a variety of its natural metabolites transcriptionally repress nuclear-factor-kappaB-mediated interleukin-8 gene expression. Eur. J. Biochem., 250, 63-71.
18. Nakamura,K. et al. (2002) Curcumin down-regulates AR gene expression and activation in prostate cancer cell lines. Int. J. Oncol., 21, 825-830.
19. Cho,J.W. et al. (2005) Curcumin inhibits the expression of COX-2 in UVB-irradiated human keratinocytes (HaCaT) by inhibiting activation of AP-1: P38 MAP kinase and JNK as potential upstream targets. Exp. Mol. Med., 37, 186-192.
20. Yan,C. et al. (2005) Gene expression profiling identifies activating transcription factor 3 as a novel contributor to the proapoptotic effect of curcumin. Mol. Cancer Ther., 4, 233-241.
21. Peehl,D.M. (2003) Growth or prostatic epithelial and stromal cells in vitro. In Russell,P.J. and Kingsley,E.A. (eds.) Prostate Cancer Methods and Protocols. Human Press, Totowa, NJ, pp. 41-57.
22. Livak,K.J. et al. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
23. Radonic,A. et al. (2004) Guideline to reference gene selection for quantitative real-time PCR. Biochem. Biophys. Res. Commum., 313 856-862.
24. Apte,R.N. et al. (2002) Interleukin-1-a major pleiotropic cytokine in tumor-host interactions. Semin. Cancer Biol., 12, 277-290.
25. Veltri,R.W. et al. (1999) Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer. Urology, 53, 139-147.
26. Brinkman,B.M. et al. (1999) Engagement of tumor necrosis factor (TNF) receptor 1 leads to ATF-2- and p38 mitogen-activated protein kinase-dependent TNF-alpha gene expression. J. Biol. Chem., 274 30882-30886.
27. Kuldo,J.M. et al. (2005) Differential effects of NF-{kappa}B and p38 MAPK inhibitors and combinations thereof on TNF-{alpha}- and IL-1{beta}-induced proinflammatory status of endothelial cells in vitro. Am. J. Physiol. Cell Physiol., 289, C1229-C1239.
28. Said,F.A. et al. (2002) TNF-alpha, inefficient by itself, potentiates IL-1beta-induced PGHS-2 expression in human pulmonary microvascular endothelial cells: Requirement of NF-kappaB and p38 MAPK pathways. Br. J. Pharmacol., 136, 1005-1014.
29. Karin,M. (1999) How NF-kappaB is activated: The role of the IkappaB kinase (IKK) complex. Oncogene, 18, 6867-6874.
30. Kato,T.Jr et al. (2003) CK2 is a C-terminal IkappaB kinase responsible for NF-kappaB activation during the UV response. Mol. Cell, 12, 829-839.
31. Winzen,R. et al. (1999) The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J, 18 4969-4980.
32. Craig,R. et al. (2000) p38 MAPK and NF-kappa B collaborate to induce interleukin-6 gene expression and release. Evidence for a cytoprotective autocrine signaling pathway in a cardiac myocyte model system. J. Biol. Chem., 275, 23814-23824.
33. Mukhopadhyay,A. et al. (2001) Curcumin downregulates cell survival mechanisms in human prostate cancer cell lines. Oncogene, 20 7597-7609.
34. Gasparian,A.V. et al. (2002) The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J. Cell Sci., 115, 141-151.
35. Kundu,J.K. et al. (2004) Resveratrol inhibits phorbol ester-induced cyclo-oxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biofactors, 21, 33-39.
36. Kim,S.O. et al. (2005) [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin. Oncogene, 24, 2558-2567.
37. Cohen,B.L. et al. (2006) Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence. Int. J. Cancer 119, 1082-1087.
38. Ricote,M. et al. (2003) Pro-apoptotic tumor necrosis factor-alpha transduction pathway in normal prostate, benign prostatic hyperplasia and prostatic carcinoma. J. Urol., 170, 787-790.
39. Corcoran, N.M. et al. (2003) Interleukin-6: Minor player or starring role in the development of hormone-refractory prostate cancer? BJU Int., 91, 545-553.
40. Michalaki,V. et al. (2004) Serum levels of IL-6 and TNF-alpha correlate with clinicopathological features and patient survival in patients with prostate cancer. Br. J. Cancer, 91, 1227.
41. Bao,B.Y. et al. (2006) 1{alpha}, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis, 27, 1883-1893.
42. Wallner,L. et al. (2006) Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Res., 66, 3087-3095.
43. Palayoor,S.T. (1999) Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene, 18, 7389-7394.
44. Jang,M. et al. (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science, 275, 218-220.
45. Hsieh,T.C. et al. (1999) Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp. Cell Res., 249, 109-115.
46. Newall,C.A. et al. (1996) Herbal Medicines: A guide for health-care professionals. Pharmaceutical Press, London.